Antimicrobial

Vaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in InfantsVaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants

Vaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants

-- Company Expects to Announce VAX-31 Infant Study Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series in Mid-2026,…

7 months ago
Kane Biotech Announces Change in US Distribution Partner for revyve™ Antimicrobial Wound GelKane Biotech Announces Change in US Distribution Partner for revyve™ Antimicrobial Wound Gel

Kane Biotech Announces Change in US Distribution Partner for revyve™ Antimicrobial Wound Gel

BioStem Technologies Signs Letter of Intent to Acquire Exclusive US Distribution Rights for revyve™ from ProgenaCare GlobalWINNIPEG, Manitoba, Nov. 27, 2024…

7 months ago
Recce Pharmaceuticals Granted Australia Patent for RECCE® Anti-InfectivesRecce Pharmaceuticals Granted Australia Patent for RECCE® Anti-Infectives

Recce Pharmaceuticals Granted Australia Patent for RECCE® Anti-Infectives

SYDNEY, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q), the Company developing a new class of synthetic…

7 months ago
Teva Takes on Antimicrobial Resistance (AMR): What You Need to KnowTeva Takes on Antimicrobial Resistance (AMR): What You Need to Know

Teva Takes on Antimicrobial Resistance (AMR): What You Need to Know

NORTHAMPTON, MA / ACCESSWIRE / November 20, 2024 / Antimicrobial resistance (AMR) happens when bacteria no longer respond to antibiotics,…

8 months ago
BioStem Technologies Signs Letter of Intent to Acquire Wound Care Products and Technologies from ProgenaCare GlobalBioStem Technologies Signs Letter of Intent to Acquire Wound Care Products and Technologies from ProgenaCare Global

BioStem Technologies Signs Letter of Intent to Acquire Wound Care Products and Technologies from ProgenaCare Global

Additions of ProgenaMatrix® and revyve™ Antimicrobial Wound Gel part of planned expansion of BioStem’s commercial product portfolioPOMPANO BEACH, Fla., Nov.…

8 months ago
Cosmos Health Reports Q3 2024 Results: Resilient Revenue and Gross Profit Amid 18.6% Expense Reduction; Stockholders’ Equity Up 8.8% to $35MCosmos Health Reports Q3 2024 Results: Resilient Revenue and Gross Profit Amid 18.6% Expense Reduction; Stockholders’ Equity Up 8.8% to $35M

Cosmos Health Reports Q3 2024 Results: Resilient Revenue and Gross Profit Amid 18.6% Expense Reduction; Stockholders’ Equity Up 8.8% to $35M

Stable revenue and gross profit despite cost-cutting initiatives, indicating the strength of underlying segments and brands.Solid liquidity position, with cash…

8 months ago
Glidewell Introduces Simply Natural(TM) Digital Dentures With Antimicrobial PropertiesGlidewell Introduces Simply Natural(TM) Digital Dentures With Antimicrobial Properties

Glidewell Introduces Simply Natural(TM) Digital Dentures With Antimicrobial Properties

Proprietary 3D-Printing Resin Used by Glidewell Has Been Shown In Vitro to Produce Dentures With Antibacterial and Antifungal Effects NEWPORT…

8 months ago
KATALYST LAUNCHES FOURTH-GENERATION FITNESS SUIT, AGAIN RAISING THE STANDARD FOR ELECTRO MUSCLE STIMULATION (EMS) TRAININGKATALYST LAUNCHES FOURTH-GENERATION FITNESS SUIT, AGAIN RAISING THE STANDARD FOR ELECTRO MUSCLE STIMULATION (EMS) TRAINING

KATALYST LAUNCHES FOURTH-GENERATION FITNESS SUIT, AGAIN RAISING THE STANDARD FOR ELECTRO MUSCLE STIMULATION (EMS) TRAINING

New Gen4 Suit Offers Enhanced Design, Optimal Fit, and Superior Durability LAS VEGAS, Nov. 13, 2024 /PRNewswire/ -- Katalyst, the leader…

8 months ago
Cosmos Health Issues Letter to ShareholdersCosmos Health Issues Letter to Shareholders

Cosmos Health Issues Letter to Shareholders

CHICAGO, IL / ACCESSWIRE / November 12, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified,…

8 months ago
Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis BullosaRelief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa

Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa

GENEVA, SWITZERLAND / ACCESSWIRE / November 11, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical…

8 months ago